Company Overview and News


Add VRTX
to your dashboard

Headline News

'This is having such a human toll': B.C. student with CF fighting for drug coverage

9h ctvnews.ca
A student at the University of Victoria with cystic fibrosis says her supply of a lifesaving drug is dwindling, and she’s growing tired of fighting the province for access to more.

Vertex Pharmaceuticals’ (VRTX) Healthy Quant Score Make it a Buy

2017-11-21 investorplace
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is one of 349 companies within the Biotechnology GICS industry group, which is in turn part of the 781 company GICS Health Care sector. VRTX's market value is $37.2 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for VRTX puts it 60 among the 349 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 158 among the 781 companies in the sector, and number 1,038 in the nearly 5,000 company Portfolio Grader universe.

Galapagos' CF Candidate Shows Potential in Phase II Study

2017-11-20 zacks
Galapagos NV (GLPG - Free Report) announced positive top-line data from a phase II study – ALBATROSS – evaluating its cystic fibrosis transmembrane conductance (“CFTR”) corrector candidate, GLPG2222, in cystic fibrosis ("CF") patients. It led to improvements in lung function. (77-0)

Strong Sales Growth Make Vertex Pharmaceuticals (VRTX) a Buy

2017-11-13 investorplace
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is ranked as a Buy using Louis Navellier's methods for investing and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for 4 months.

Vertex Gets CHMP Recommendation for Orkambi Label Expansion

2017-11-13 zacks
Vertex Pharmaceuticals Inc. (VRTX - Free Report) announced that the Committee for Medicinal Products for Human Use ("CHMP") has recommended approval of a label expansion for Orkambi in Europe. The company is seeking extension of its marketing authorization for Orkambi to include use in children with cystic fibrosis ("CF") who are aged between 6 and 11 years and have two copies of the F508del mutation. (63-1)

Earnings Review and Free Research Report: Vertex’s Revenue Soared 40%; Adjusted EPS Rocketed 212%

2017-11-13 accesswire
LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=VRTX, following the Company's reporting of its third quarter fiscal 2017 operating results on October 25, 2017. The drugmaker increased its total 2017 CF product revenue guidance, and re-affirmed its total combined GAAP and non-GAAP research and development (R&D) and selling, general, and administrative (SG&A) expenses forecasts. (18-0)

Vertex Pharmaceuticals (VRTX) a Buy on Strong Sales Growth

2017-11-07 investorplace
As one of the 785 companies in the GICS Health Care sector Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a member of the 349 company Biotechnology GICS industry group within this sector. VRTX's market value is $37.9 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for VRTX puts it 81 among the 349 companies in this industry group, putting in the top quartile; in the top half of the sector with a ranking of 222 among the 785 companies in the sector, and number 1,463 in the nearly 5,000 company Portfolio Grader universe.

Your Daily Pharma Scoop: Progenics Looks Promising, Big Week For Dynavax, Keryx Ahead Of Catalyst

2017-11-06 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (692-4)

Your Daily Pharma Scoop: Gilead In NASH, Geron Gets A Boost, AstraZeneca's Oncology Portfolio

2017-11-01 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about changes and additions to the daily scoop. (498-1)

Sarepta Therapeutics Expects Robust Revenue Growth for 2017

2017-11-01 marketrealist
In its 3Q17 earnings conference call, Sarepta Therapeutics (SRPT) raised its 2017 revenue guidance from the previously projected range of $125 million–$130 million to $150 million–$155 million. Its Duchenne muscular dystrophy (or DMD) drug Exondys 51 reported revenues close to $46 million, which was significantly higher than what Wall Street projected. (84-0)

Your Daily Pharma Scoop: Gilead's Unappreciated Opportunity, Merck's Keytruda Stumble, Epizyme's Positive Results

2017-10-30 seekingalpha
Epizyme’s tazemetostat showed positive results in pediatric patients with relapsed or refractory INI1-negative molecularly defined solid tumors. (509-1)

Analyst Recommendations for Vertex Pharmaceuticals in October

2017-10-28 marketrealist
After 3Q17, Vertex Pharmaceuticals (VRTX) increased its guidance for cystic fibrosis product revenues, from $1.87 billion–$2.1 billion to $2.10 billion–$2.15 billion. Vertex Pharmaceuticals expects Orkambi and Kaydeco to generate net revenues of $1.29 billion–$1.32 billion and $810.0 million–$830.0 million, respectively, in fiscal 2017. (44-0)

Vertex Pharmaceuticals’ Performance in 3Q17

2017-10-28 marketrealist
In 3Q17, Vertex Pharmaceuticals (VRTX) generated revenues of $578.0 million, which was a ~40.0% rise YoY (year-over-year) and a ~6.0% rise QoQ (quarter-over-quarter). Its net income was ~$18.0 million. (1-1)

Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises 2017 View

2017-10-26 zacks
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) reported third-quarter 2017 earnings per share of 53 cents, which beat the Zacks Consensus Estimate of 37 cents and came ahead of the year-ago earnings of 17 cents. Strong product revenues led to higher profits in the quarter. (111-0)

5 Biotech Stocks Getting Battered Too Hard for Comfort | InvestorPlace

2017-10-26 investorplace
U.S. equities are rebounding from Wednesday’s weakness with a tepid rally on Thursday that suggests the bulls aren’t fully confident in their abilities to sustain the historic post-August uptrend. The catalyst for the rebound was a “dovish taper” decision by the European Central Bank, which promised to extend their bond buying program into 2018, albeit at a diminished rate. (181-1)

CUSIP: 92532F900